Introduction
Most patients with acute myeloid leukemia (AML) respond initially to induction combination chemotherapy, but relapse and die from chemo-resistant disease or complications of therapy. 1 Even with advances in treatment including retinoic acid, antibody targeted chemotherapy and stem cell transplant, the prognosis remains grim, especially for the elderly and those with poor-risk cytogenetics. 2 Development of new agents with mechanisms of action which can bypass the multi-drug resistance phenotype and selectively target leukemia progenitors is needed.
One novel class of agents are fusion proteins composed of cytotoxic catalytic toxins covalently linked to AML-selective peptide ligands. The ligand directs the molecule to the surface of the leukemic blast and facilitates its internalization. The toxin then escapes to the cytosol and inhibits critical cell functions leading to cell death. We chose to construct AMLdirected fusion proteins with diphtheria toxin (DT). DT is a 535 amino acid residue protein with three domains. 3 The C-terminal domain (amino acid residues 390-535) has a ␤-sheet-rich tertiary structure and functions to bind the protein to the heparin-binding epidermal growth factor (EGF)-like cell surface receptor. 4 The middle domain (amino acid residues 201-389) is rich in amphipathic ␣-helices and facilitates translocation of the catalytic domain to the cytosol. 5 The N-terminal domain (amino acid residues 1-200) is an ADP-ribosylase and catalytically adds ADP to the diphthamide residue of elongation factor 2 (EF2) leading to inactivation of protein synthesis. 6 The C-terminal receptor-binding domain has been replaced with alternative ligands to generate fusion proteins. 7 In our first effort to target AML with fusion proteins, we prepared and tested DT 388 GMCSF composed of the catalytic and translocation domains of DT (DT 388 ) fused to human granulocyte-macrophage colony-stimulating factor (GM-CSF). 8 In a phase I clinical study, DT 388 GMCSF produced some clinical remissions in highly chemotherapy refractory patients. 9 Doselimiting toxicity was liver injury.
To improve upon the efficacy and specificity of the fusion protein, we have engineered DT 388 IL3 composed of DT 388 fused to human interleukin-3. 10 Many human AML blasts proliferate in response to IL-3 and express the IL-3 receptor. 11 In vitro studies of DT 388 IL3 showed potent cell kill (greater than 1 log) from 36% of patients under conditions which produced minimal damage to normal hematopoietic stem cells. [12] [13] [14] [15] We now report the in vivo anti-leukemia efficacy of DT 388 IL3. Immunocompromised mice engrafted with human IL-3 receptor positive AML blasts were used. This model has been previously established and standardized in our laboratory. 16 Leukemic mice were treated with various fusion proteins and other cytotoxic compounds. The data below demonstrate substantial killing of malignant progenitors in vivo with DT 388 IL3 with a potency similar to current clinically approved cytotoxic agents.
Materials and methods

Cells
TF-1 human leukemia cells transfected with v-Src (TF/v-SRC) were grown as previously described in RPMI 1640 medium supplemented with 10% fetal bovine serum, penicillin/ streptomycin and l-glutamine.
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Animals
Balb-c SCID/SCID mice (female; age 6 weeks) were obtained from Jackson Laboratories (Bar Harbor, ME, USA) and maintained in micro-isolator cages housed in laminar flow cubicles in a positive pressure room. The temperature of the room Leukemia ranged from 22 to 25°C. The water was autoclaved and provided ad libitum. The food was irradiated and provided ad libitum. The mice were allowed to adjust to their new environment for 1 week. The mice were then irradiated with 350 cGy total body irradiation to diminish natural killer activity. 17 After 24 h of observation, the mice were injected either i.v. via tail vein, i.p. or s.c. with 20 million TF/v-SRC cells diluted in 0.2 ml of phosphate buffered saline (PBS; BioWhittaker, Walkersville, MD, USA) with 1% bovine serum albumin (BSA; Sigma, St Louis, MO, USA). After completion of all injections, cells from residual syringes were Ͼ90% viable by Trypan Blue exclusion.
Drugs
DT 388 IL3 was prepared as stocks in 0.25 m sodium chloride/0.02 m Tris pH 8 at 1 mg/ml in our laboratory as previously described and stored in aliquots at −80°C.
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DT 388 GMCSF was prepared as stocks in PBS at 1.5 mg/ml as previously described and was stored at −80°C.
8 DAB 389 IL2 (ONTAK) was obtained from Ligand Pharmaceuticals (San Diego, CA, USA), diluted in PBS to 0.15 mg/ml and stored at 4°C. Cytarabine was obtained from Sigma, diluted in sterile water to 1 mg/ml and stored at 4°C. Anti-CD33-calicheamicin (Mylotarg) was obtained from Wyeth Laboratories (Marietta, PA, USA) and dissolved in normal saline at 5 mg/ml immediately prior to use.
Efficacy studies
Groups of 20 animals received i.p. injections of individual agents beginning 24 h after leukemia cell inoculation. Animals received 0.2 ml of saline or PBS/1% BSA containing DT 388 IL3, DT 388 GMCSF, DAB 389 IL2, or cytarabine i.p. daily for 5 days. Anti-CD33-calicheamicin was given i.p. on days 1 and 14. A total of 245 mice were used. The mice were examined daily for overall activity and for the presence of masses. Moribund mice were killed.
Autopsies
Moribund SCID mice were killed painlessly by standard CO 2 asphyxiation, consistent with the recommendations of the Panel on Euthanasia of the American Veterinary Medical Association. All other mice were killed when mass size was Ն15 mm in diameter. If a mass never developed or did not reach 15 mm in diameter, the mouse was killed at day 120. Samples from major organs and abdominal masses were removed, fixed in 4% buffered formaldehyde, dehydrated and embedded in paraffin. Sections were stained with hematoxylin and eosin and examined under the microscope.
Statistical analysis
Survival was analyzed by the Kaplan-Meier method and median disease-free survival (DFS) time was determined using GraphPad Prism software. The Mantel-Cox (logrank) test was used for comparison of DFS between the groups.
Results
The median disease-free survival (DFS) of control mice injected i.v., i.p. or s.c. with 20 million TF/v-SRC cells was 37 days (n = 45), 35 days (n = 20) and 21 days (n = 20), respectively ( Figure 1 ). The distribution of the leukemia varied with the route of inoculation. I.V. inoculated animals showed leukemic deposits in abdominal masses along the vena cava and aorta. These animals also had infiltration of the liver, kidney, adrenals, skeletal muscle, stomach and pancreas. An adrenal infiltrate is shown in Figure 2 (arrow). I.P. inoculated animals showed almost exclusively intra-abdominal masses and injection tract tumors. One such infiltrative focus in the colon submucosa is shown in Figure 2 (arrow) . S.C. inoculated animals had injection site tumors. Figure 2 demonstrates the infiltrative nature of these tumor cells in the dermis (arrow). The data demonstrate the aggressive nature of this leukemic cell type and its ability to recapitulate extensive infiltrative disease in various organ sites.
DT 388 IL3 significantly improved median DFS of the leukemic SCID mice (Figure 1 Each leukemia model (i.v., i.p. and s.c.) is different both with regard to disease distribution and time course. We chose the s.c. model for additional studies because this model produced less animal morbidity and gave a more rapid endpoint. Animals killed at day 120 were studied by histopathology and no evidence of leukemia was observed in these animals. A few of the i.v. TF/v-SRC animals died early post-inoculation from complications of rapid i.v. infusions and these animals were censored.
The positive controls and negative control consisted of drugs currently used in the treatment of patients with AML and lymphoma, respectively. As shown in Table 1 , these agents yielded effects on median DFS consistent with their known clinical activity. Cytarabine prolonged median DFS of s.c. leukemic mice by 172% compared to controls (P Ͻ 0.0001); DT 388 GMCSF prolonged median DFS of s.c. leukemic mice by 67% (P Ͻ 0.0001); and anti-CD33-calicheamicin prolonged median DFS of these s.c. leukemic mice by 47% (P = 0.0004). This compares with the 48% prolongation in median DFS produced by DT 388 IL3 in this model (P = 0.0006, Figure 1c ). In contrast, DAB 389 IL2 treatment produced a non-significant shortening of median DFS of s.c. leukemic mice by 13% (P = 0.21, Figure 1d ).
Discussion
Our observation extends the observation of Feuring-Buske et al 15 of in vivo anti-leukemia efficacy for DT 388 IL3. In the study of Feuring-Buske et al, NOD/SCID mice were inoculated i.v. with patient AML blasts and half were treated i.p. daily for 5 days with 1 g DT 388 IL3. 15 Treated animals had mean reductions in bone marrow AML engraftment of 83% and 57% at 1 and 3 months, respectively. In 2/6 AML samples, all leukemia cells were eliminated, and in another two samples repeated monthly treatments enhanced AML kill. Since there was a limited supply of patient material, additional studies were not possible. The TF/v-SRC cells grown in SCID mice were sensitive in vivo to DT 388 IL3. Thus, our results extend the previous findings, and provide an inexhaustible differentiated leukemia model system for testing drug combinations and enhancers.
The different routes of tumor administration yielded different forms of dissemination and growth of leukemia in vivo. Based on animal appearance and histology, the i.v. TF/v-SRC Leukemia SCID model resembled widespread human leukemia with involvement of multiple organs. Because of the varying condition of different i.v. inoculated animals, the endpoint for disease-free survival was difficult to determine. Hence, longer DFS and a wider range of DFS was observed with this model. Animals became moribund, and were killed. The i.p. and s.c. models showed localized leukemic deposits. While the i.v. inoculated animals have evidence of hematogenous disseminated disease which closely resembles most human leukemias, the extramedullary disease deposits observed in the i.p. and s.c. inoculated animals infiltrated similarly to human chloromas and had similar histology to that reported in the original patient from which TF1 cells were isolated. 18 Endpoints of localized disease in the abdominal cavity and subcutaneous tissues were easier to observe, and animals appeared to have minimal distress or morbidity. The shorter diseasefree survivals for the i.p. and s.c. model reflected the easier identification of measurable disease in these animals. We chose the s.c. model to test additional controls, because of the accuracy of the disease endpoint, ease of animal inoculation and the reduction in animal suffering.
Our results with the human IL-3 DT fusion protein are similar to previous observations with a murine IL-3 containing DT fusion molecule, DT 390 mIL3. 19 The maximal tolerated dose of DT 390 mIL3 was 0.05 g/day i.p. for 5 days. The dose-limiting toxicity was myelosuppression with thrombopenia-associated bleeding. C3H/HeJ mice were inoculated i.p. with 1000 32Dp210 mouse leukemia cells, and half were treated, beginning 24 h later, with five daily i.p. injections of 0.05 g/day DT 390 mIL3. Treatment with DT 390 mIL3 produced a significant anti-leukemia effect in vivo (P Ͻ 0.025). Four of five control animals died by day 20 from leukemia, and the last animal died from leukemia on day 68. In contrast, one of five treated animals died early without leukemia, and the remaining four animals survived without leukemia until day 82 when one of the animals died with leukemia. While there was anti-leukemia activity in vivo with the murine DT fusion protein with mouse leukemia, the greater toxicity suggests caution in the development of the human DT 388 IL3. Patients, in contrast to rodents, can be supported with platelet and red cell transfusions, but preliminary toxicology studies in receptor-bearing non-human primates are warranted.
DT 388 IL3 had significantly less potency in vivo than cytarabine. Thus, we do not anticipate that this fusion protein would replace or substitute for standard chemotherapy of AML. Nevertheless, targeted therapies of AML may be useful -even when not as active as standard cytotoxic drugs. They may have a role for palliative treatment of refractory patients or in combination with standard drugs. DT 388 IL3 had similar potency as DT 388 GMCSF or anti-CD33-calicheamicin in this model. Both of these agents have yielded clinical responses in AML patients. 9, 20 Thus, further preclinical development of DT 388 IL3 appears warranted.
DT 388 GMCSF has been administered systemically to 37 patients with relapsed or refractory AML in a single arm interpatient dose escalation study and clinical remissions have been observed. 9 The DT 388 GMCSF produced dose-limiting liver injury associated with binding to GMCSF receptors on liver macrophages. We have not observed IL-3 receptors on liver macrophages nor DT 388 IL3-mediated liver injury in either rodent or monkey models to date (unpublished observations). Hence, we anticipate a different toxicity profile and perhaps wider therapeutic index with DT 388 IL3. Further testing in the receptor cross-reactive cynomolgus monkey model will be necessary prior to clinical development. Nevertheless, this agent may be an attractive addition to a growing number of targeted therapeutics for AML.
